Humana AB (publ)

OM:HUM Stock Report

Market Cap: SEK 1.9b

Humana Valuation

Is HUM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HUM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 87.78
Fair Value
59.1% undervalued intrinsic discount
2
Number of Analysts

Below Fair Value: HUM (SEK35.9) is trading below our estimate of fair value (SEK87.78)

Significantly Below Fair Value: HUM is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HUM?

Key metric: As HUM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for HUM. This is calculated by dividing HUM's market cap by their current earnings.
What is HUM's PE Ratio?
PE Ratio15x
EarningsSEK 124.00m
Market CapSEK 1.86b

Price to Earnings Ratio vs Peers

How does HUM's PE Ratio compare to its peers?

The above table shows the PE ratio for HUM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average27.2x
AMBEA Ambea
13.2x11.5%SEK 8.0b
ATT Attendo
20.2x23.7%SEK 8.1b
EQL EQL Pharma
66.8x53.3%SEK 2.1b
DEDI Dedicare
8.8xn/aSEK 584.3m
HUM Humana
15x44.7%SEK 1.9b

Price-To-Earnings vs Peers: HUM is good value based on its Price-To-Earnings Ratio (15x) compared to the peer average (27.2x).

Price to Earnings Ratio vs Industry

How does HUM's PE Ratio compare vs other companies in the European Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
HUM 15.0xIndustry Avg. 19.7xNo. of Companies8PE01020304050+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: HUM is good value based on its Price-To-Earnings Ratio (15x) compared to the European Healthcare industry average (19.7x).

Price to Earnings Ratio vs Fair Ratio

What is HUM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HUM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15x
Fair PE Ratio34.2x

Price-To-Earnings vs Fair Ratio: HUM is good value based on its Price-To-Earnings Ratio (15x) compared to the estimated Fair Price-To-Earnings Ratio (34.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HUM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 35.90
SEK 50.50
+40.7%
5.0%SEK 53.00SEK 48.00n/a2
Jan ’26SEK 35.65
SEK 50.50
+41.7%
5.0%SEK 53.00SEK 48.00n/a2
Dec ’25SEK 36.70
SEK 50.50
+37.6%
5.0%SEK 53.00SEK 48.00n/a2
Nov ’25SEK 37.85
SEK 49.00
+29.5%
8.2%SEK 53.00SEK 45.00n/a2
Oct ’25SEK 35.40
SEK 39.50
+11.6%
13.9%SEK 45.00SEK 34.00n/a2
Sep ’25SEK 32.55
SEK 39.50
+21.4%
13.9%SEK 45.00SEK 34.00n/a2
Aug ’25SEK 30.75
SEK 39.50
+28.5%
13.9%SEK 45.00SEK 34.00n/a2
Jul ’25SEK 33.85
SEK 37.50
+10.8%
20.0%SEK 45.00SEK 30.00n/a2
Jun ’25SEK 32.40
SEK 35.00
+8.0%
14.3%SEK 40.00SEK 30.00n/a2
May ’25SEK 29.80
SEK 35.00
+17.4%
14.3%SEK 40.00SEK 30.00n/a2
Apr ’25SEK 24.55
SEK 33.50
+36.5%
19.4%SEK 40.00SEK 27.00n/a2
Mar ’25SEK 25.30
SEK 33.50
+32.4%
19.4%SEK 40.00SEK 27.00n/a2
Feb ’25SEK 25.85
SEK 34.50
+33.5%
15.9%SEK 40.00SEK 29.00n/a2
Jan ’25SEK 28.15
SEK 37.00
+31.4%
21.6%SEK 45.00SEK 29.00SEK 35.652
Dec ’24SEK 27.65
SEK 37.00
+33.8%
21.6%SEK 45.00SEK 29.00SEK 36.702
Nov ’24SEK 26.70
SEK 34.50
+29.2%
15.9%SEK 40.00SEK 29.00SEK 37.852
Oct ’24SEK 26.60
SEK 34.50
+29.7%
15.9%SEK 40.00SEK 29.00SEK 35.402
Sep ’24SEK 29.60
SEK 34.50
+16.6%
15.9%SEK 40.00SEK 29.00SEK 32.552
Aug ’24SEK 28.00
SEK 34.50
+23.2%
15.9%SEK 40.00SEK 29.00SEK 30.752
Jul ’24SEK 22.20
SEK 17.00
-23.4%
14.4%SEK 20.00SEK 14.00SEK 33.853
Jun ’24SEK 15.04
SEK 17.00
+13.0%
14.4%SEK 20.00SEK 14.00SEK 32.403
May ’24SEK 14.46
SEK 16.67
+15.3%
17.2%SEK 20.00SEK 13.00SEK 29.803
Apr ’24SEK 14.76
SEK 17.33
+17.4%
11.9%SEK 20.00SEK 15.00SEK 24.553
Mar ’24SEK 14.34
SEK 17.33
+20.9%
11.9%SEK 20.00SEK 15.00SEK 25.303
Feb ’24SEK 21.35
SEK 45.67
+113.9%
47.9%SEK 70.00SEK 17.00SEK 25.853
Jan ’24SEK 38.50
SEK 64.33
+67.1%
6.3%SEK 70.00SEK 61.00SEK 28.153
Analyst Price Target
Consensus Narrative from 2 Analysts
SEK 50.50
Fair Value
28.9% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/18 07:17
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Humana AB (publ) is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel ThorssonABG Sundal Collier
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB
Mikael HolmDanske Bank